News >

Lead Investigator Highlights Apalutamide Efficacy in Metastatic Castration-Sensitive Prostate Cancer

Ellie Leick
Published: Monday, Jul 01, 2019

Kim N. Chi, MD

Kim N. Chi, MD
With improvements in radiographic progression-free survival (rPFS) and overall survival (OS), Kim Chi, MD, explained that the next-generation androgen receptor (AR) inhibitor apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) could be a new standard of care for patients with metastatic castration-sensitive prostate cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication